The AMBASSADOR (A031501) trial met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma

Secondary analysis results from the NRG Oncology-RTOG 0617 clinical trial comparing standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer indicate that intensity-modulated radiation therapy should be used to treat locally advanced disease to reduce risk of severe pulmonary toxicity and radiation exposure to the heart

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung-MAP trial has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance

The CABINET (A021602) clinical trial met its primary endpoint at an interim analysis in both of the trial’s cohorts, demonstrating statistically significant and clinically meaningful improvements in progression-free survival; CABINET enrolled patients with either advanced pancreatic neuroendocrine tumors or advanced extra-pancreatic neuroendocrine tumors who experienced progression after prior systemic therapy

Results of large pragmatic trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

The Alliance Board of Directors is pleased to announce the appointments of Jonathan E. Rosenberg, MD and Matthew Galsky, MD as Co-Chairs of the Alliance Genitourinary Committee

NRG Oncology recently announced Walter J. Curran, Jr., MD, FACR, FASCO, as its first recipient of the organization’s new Gold Medal award, honoring distinguished and extraordinary service to NRG Oncology and recognizing the awardee’s significant contributions to the field of oncology

NRG Oncology recently announced the addition of three new leaders in various areas of the organization’s committee structure

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy; the trial is for adults with cancers that are getting worse after being treated with taxane-based chemotherapy